BTBP(SH:600161) Zhi Tong Cai Jing·2025-08-05 09:18Core Viewpoint - TianTan Bio (600161.SH) announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. has completed clinical trials for its product "Recombinant Human Coagulation Factor VIII for Injection" in the population under 12 years old, achieving significant results in reducing bleeding frequency and improving joint health and quality of life scores [1] Group 1: Clinical Trial Results - The Phase III clinical trial results for the product in the under-12 age group show that routine preventive treatment significantly reduces bleeding frequency in children [1] - Improvements were observed in the patients' joint health score (HJHS score), number of target joints, and quality of life score (CHO-KLAT score) [1] - The product effectively controls breakthrough bleeding during the prevention period [1] Group 2: Safety Analysis - Safety analysis indicates that the drug demonstrates good safety for patients with Hemophilia A in this age group during clinical application [1]